Product image of Miniflampatch (Diclofenac Epolamine) supplied by GNH India

Miniflampatch

Active Ingredient:
Diclofenac Epolamine
Origin:
EU

Miniflampatch (Diclofenac Epolamine)

Diclofenac epolamine, the active ingredient in Miniflampatch, is a nonsteroidal anti-inflammatory drug presented as a transdermal patch for cutaneous use. It is employed to alleviate mild to moderate musculoskeletal pain and to diminish localized inflammation in adults.

GNH India supplies Miniflampatch as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this EU‑market product. The company adheres to stringent quality standards and offers comprehensive logistics support to meet the needs of global healthcare providers.

Manufacturer / TM Owner

Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Diclofenac epolamine, delivered via a transdermal patch, acts on inflammatory pathways to provide analgesic and anti‑inflammatory effects.

  • Mild to moderate musculoskeletal pain: reduces pain and improves function in muscles, joints and tendons.
  • Localized soft‑tissue inflammation: decreases swelling and discomfort at the application site.
  • Post‑traumatic or overuse injuries: alleviates pain associated with sprains, strains and minor injuries.

How It Works

  • Diclofenac epolamine penetrates the skin and inhibits cyclooxygenase (COX‑1 and COX‑2) enzymes, leading to reduced synthesis of prostaglandins that mediate inflammation, pain and fever. By lowering local prostaglandin levels, the patch provides targeted analgesic and anti‑inflammatory effects while limiting systemic exposure.

Side Effects

Adverse reactions may occur at the application site or systemically.

Common Side Effects

  • Skin irritation: redness or mild discomfort at the patch site.
  • Itching or burning sensation: transient sensation during or after removal.
  • Dryness or peeling of the skin.
  • Localized rash or contact dermatitis.
  • Mild swelling around the application area.

Serious or Rare Side Effects

  • Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat.
  • Stevens‑Johnson syndrome or toxic epidermal necrolysis: extensive skin blistering and detachment.
  • Severe skin ulceration or necrosis at the site.
  • Systemic NSAID toxicity: renal impairment or hepatic dysfunction.
  • Cardiovascular events: increased risk of heart attack or stroke in susceptible individuals.

Precautions & Warnings

When using Miniflampatch, consider the following safety measures.

  • Assess skin integrity: ensure the application site is intact and free of lesions.
  • Avoid use on infected or damaged skin: risk of increased absorption and irritation.
  • Limit duration: follow prescriber instructions to prevent excessive systemic exposure.
  • Monitor for cardiovascular risk: NSAIDs may increase risk in patients with heart disease.
  • Avoid concurrent use of other topical NSAIDs: may increase local toxicity.
  • Store at room temperature: keep in the original pouch, protect from moisture and direct sunlight.

Avoid Interactions

Diclofenac epolamine may interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid)

  • Concurrent oral anticoagulants: increased bleeding risk.
  • Systemic NSAIDs: additive gastrointestinal toxicity.
  • Lithium therapy: diclofenac may raise lithium serum levels.

Moderate Interactions (Monitor Closely)

  • Diuretics: may reduce renal clearance of diclofenac.
  • Corticosteroids: combined use can raise risk of gastrointestinal ulceration.

Frequently Asked Questions

Miniflampatch is a transdermal patch containing diclofenac epolamine. It is applied to the skin to relieve mild to moderate musculoskeletal pain and to reduce localized inflammation associated with conditions such as sprains, strains, tendonitis and other soft‑tissue injuries.

Diclofenac epolamine penetrates the skin and blocks cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This inhibition lowers prostaglandin production, which are key mediators of inflammation and pain, thereby providing targeted analgesic and anti‑inflammatory effects at the site of application.

The prescribed dose of Miniflampatch is determined by the treating healthcare professional. Typically, a single patch is applied to clean, dry skin for a specified period, and the prescriber decides the frequency and duration based on the patient’s condition and response.

Safety data for diclofenac epolamine patches in pregnancy and lactation are limited. Healthcare providers should weigh potential risks and benefits before prescribing to pregnant or nursing women, and patients should discuss any concerns with their clinician.

To order Miniflampatch, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral NSAIDs, Miniflampatch delivers diclofenac directly to the affected area, potentially reducing systemic exposure and associated gastrointestinal or cardiovascular risks. Compared with other topical NSAID patches, it offers a similar mechanism of action but may differ in adhesive properties, patch size and approved indications.

Store Miniflampatch at room temperature, ideally below 25 °C, in its original packaging. Keep the patch away from moisture, direct sunlight and extreme heat. Do not expose it to temperatures above the recommended range, and keep it out of reach of children.

The patch is applied to clean, dry, intact skin on the area of pain. Remove the protective liner, press the adhesive side firmly for several seconds, and wear it for the duration prescribed by the clinician. After use, gently peel off the patch and discard it according to local regulations.

Serious risks include severe allergic reactions such as anaphylaxis, rare skin disorders like Stevens‑Johnson syndrome or toxic epidermal necrolysis, and systemic NSAID toxicity that can affect kidney or liver function. Patients should seek immediate medical attention if they experience signs of a severe reaction.

Miniflampatch should be avoided in individuals with known hypersensitivity to diclofenac, other NSAIDs, or any component of the patch. It is also contraindicated on infected, broken or inflamed skin, and in patients with a history of severe cardiovascular, renal or hepatic disease unless specifically advised by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Diclofenac Epolamine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT